Back to search

France· FR:67199506

CARDIOXANE 500 mg, poudre pour solution pour perfusion

A dexrazoxane product containing chlorhydrate de dexrazoxane, registered in France by CNX THERAPEUTICS IRELAND LIMITED (IRLANDE). The same ATC class is registered in 15 of our 19 countries.

ATC V03AF02

Checked against Base de données publique des médicaments — BDPM (France) on

Informational only — not a medical device.

SOURCE REGISTER · FRBase de données publique des médicament…normalisedCARDIOXANE 500 mg, poudre pour soluti…ATCV03AF02REGISTER NO.FR:67199506PACKS LISTED1CHECKEDSeptember 12, 2026

Where it is registered

Dexrazoxane is registered in 15 of 19 countries.

Countries holding a registration under ATC V03AF02 (dexrazoxane), each read from that country’s own register.

  • This record: France, from Base de données publique des médicaments — BDPM (France)
  • 8 of them publish a price we can compare per daily dose

Dexrazoxane · ATC V03AF02

15 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Germany
  • Icelandprice
  • Ireland
  • Japan
  • Netherlands
  • Norwayprice
  • Polandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of dexrazoxane costs, country by country.

Normalised to the WHO defined daily dose (1.5 g), so markets compare like for like.

  • 1 market with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown

Dexrazoxane · price per daily dose (1.5 g)

USD · FX 28 Sept 2026

  • FI Finland$8.88
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

Base de données publique des médicaments — BDPM (France)
Active substance
CHLORHYDRATE DE DEXRAZOXANE
Manufacturer
CNX THERAPEUTICS IRELAND LIMITED (IRLANDE)
Country
France (FR)
ATC code
V03AF02
ATC class
Dexrazoxane
Defined daily dose
1.5 g, P
Reimbursed
No
Source register
Base de données publique des médicaments — BDPM (France)
Last checked
September 12, 2026

Packs & prices · 1

  • cip13
    3400955908395
    1 flacon(s) en verre brun

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

8 interactions on record for dexrazoxane.

Graded by severity as the source publishes them — 2 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Dexrazoxane · interactions on record

8 records

  • 2 severe
  • 6 moderate

Most severe, free to view

  • Talimogene laherparepvecL01XL02severe
  • Talimogen laherparepvecL01XX51severe
  • Lactobacillus acidophilusJ07AX04moderate
  • DoxorubicinL01DB01moderate
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Dexrazoxane in 14 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All dexrazoxane products

Authorised across Europe · EMA

The same active substance is authorised in 14 EEA countries. Names it is sold under:

  • Austria · Cyrdanax
  • Czechia · Cyrdanax
  • Germany · Cardioxane, Cyrdanax
  • Spain · Cardioxane
  • United Kingdom (Northern Ireland) · Cardioxane
  • Hungary · Cyrdanax
  • Iceland · Savene
  • Italy · Cardioxane
  • Liechtenstein · Savene
  • Netherlands · Cardioxane
  • Norway · Savene
  • Poland · Cyrdanax
  • Romania · Cyrdanax
  • Slovakia · Cyrdanax

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Base de données publique des médicaments — BDPM (France). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/8cecdf7b-8572-46af-a899-4daff9c011a4
GET /v1/drugs/8cecdf7b-8572-46af-a899-4daff9c011a4?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "cis": "67199506",
  "date_amm": "1995-10-09",
  "type_amm": "Procédure de reconnaissance mutuelle",
  "numero_ue": null,
  "substance": "CHLORHYDRATE DE DEXRAZOXANE",
  "atc_source": "fr_atc_restore_2026-09-06",
  "statut_amm": "Autorisation active",
  "statut_bdm": null,
  "forme_pharmaceutique": "poudre pour solution pour perfusion",
  "voies_administration": "intraveineuse",
  "etat_commercialisation": "Commercialisée",
  "surveillance_renforcee": "Non"
}

See everything about dexrazoxane.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.